Barely Significant
← all excerpts

NEO6860, modality-selective TRPV1 antagonist: a randomized, controlled, proof-of-concept trial in patients with osteoarthritis knee pain.

Pain Rep · 2018 · PMC6344137 · PMID 30706039

Europe PMCDOI
1
hedged sentence
0.0736
closest p · 1.5× alpha
0.0736
boldest claim

The sentences

close to significanceP = 0.0736so close (0.05 < p ≤ 0.1)
Differences were statistically significant when comparing naproxen with placebo ( P = 0.0201) and close to significance when comparing NEO6860 with placebo ( P = 0.0736). 3.3.5.

also in 2,130 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.